Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Fineline Cube Jun 29, 2026
Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older

Fineline Cube Jun 29, 2026
Company Drug

Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval

Fineline Cube Jun 29, 2026
Company Deals

Ping An Good Doctor Partners with Vcanbio to Pioneer Cell Health Management Services in China

Fineline Cube Jan 31, 2024

Ping An Healthcare and Technology Co., Ltd (HKG: 1833), commonly referred to as PingAn Good...

Company Deals Hospital

Mabwell Bioscience Extends Research Partnership with Fudan University Cancer Center

Fineline Cube Jan 31, 2024

Mabwell (Shanghai) Bioscience Co., Ltd., (SHA: 688062) has announced the renewal of its strategic research...

Company Drug

Hengrui Pharmaceuticals Scores First-Mover Status with FDA Approval for Generic Astagraf XL

Fineline Cube Jan 30, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Deals

Gilead Increases Stake in Arcus Biosciences and Invests in Anti-TIGIT Program

Fineline Cube Jan 30, 2024

Gilead (NASDAQ: GILD) has strengthened its 2020 collaboration agreement with US-based Arcus Biosciences (NYSE: RCUS)...

Company Drug

Takeda’s Gammagard Liquid Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Jan 30, 2024

The US Food and Drug Administration (FDA) has granted regulatory approval for Takeda’s (TYO: 4502)...

Company Hospital Policy / Regulatory

Shaanxi Province Unveils Ambitious Three-Year Plan to Boost Traditional Chinese Medicine Industry

Fineline Cube Jan 30, 2024

The provincial government of Shaanxi has unveiled the “Three Year Action Plan for Empowering Shaanxi...

Company Drug

AstraZeneca’s Enhertu Receives Priority Review for Expanded HER2-positive Solid Tumor Indication

Fineline Cube Jan 30, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that an indication extension filing for...

Company

MicroPort Scientific Corp. Forecasts 31%-34% Revenue Growth for Subsidiary MicroPort Endovascular in 2023

Fineline Cube Jan 30, 2024

Shanghai-based medical device conglomerate MicroPort Scientific Corp., (HKG: 0853) has issued a revenue and growth...

Company Deals

SANDT Secures Nearly RMB 200 Million to Boost X-ray System Development and Manufacturing

Fineline Cube Jan 30, 2024

SANDT, a Shanghai-based specialist in X-ray systems, has reportedly secured nearly RMB 200 million (USD...

Company Deals

Joincare Pharmaceutical Group Secures USD 100 Million Loan from IFC for Expansion

Fineline Cube Jan 30, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a China-based pharmaceutical company, has announced securing...

Company Deals

South Korean Duo GC Wellbeing and YooYoung Pharmaceutical Target Chinese Filler Market

Fineline Cube Jan 30, 2024

South Korean health and functional food manufacturer GC Wellbeing and YooYoung Pharmaceutical have formed a...

Company Deals

TYK Medicines Files for IPO on HKSE Amid Rising Losses and Expanding Drug Pipeline

Fineline Cube Jan 29, 2024

Zhejiang-based TYK Medicines Inc. (HKG: 2410) has filed for an initial public offering (IPO) on...

Company Drug

Bristol Myers Squibb’s Subcutaneous Opdivo Shows Noninferiority in Phase III ccRCC Trial

Fineline Cube Jan 29, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) this week announced preliminary Phase III data demonstrating that...

Company

Blue Sail Medical Secures RMB 900 Million Investment for R&D and Capacity Expansion

Fineline Cube Jan 29, 2024

Blue Sail Medical Co., Ltd (SHE: 002382) has announced that its wholly owned subsidiary, Blue...

Company Deals

3D Medicines Partners with Sino Cellbiomed to Advance Tumor Immunotherapy Development

Fineline Cube Jan 29, 2024

3D Medicines (HKG: 1244), a China-based oncology specialist, has entered into a partnership with Sino...

Company Deals

Mindray to Acquire 21.12% Stake in APT Medical for RMB 6.652 Billion

Fineline Cube Jan 29, 2024

Mindray (SHE: 300760), a leading China-based medtech firm, has announced plans to acquire a 21.12%...

Company Drug

Johnson & Johnson’s Rybrevant and Lazertinib Filings Accepted for Review by CDE

Fineline Cube Jan 29, 2024

The Center for Drug Evaluation (CDE) has confirmed that Johnson & Johnson’s (J&J, NYSE: JNJ)...

Company Drug

EMA’s CHMP Endorses Bristol Myers Squibb’s CAR-T Therapy Abecma for Multiple Myeloma

Fineline Cube Jan 29, 2024

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Drug

Dupixent by Sanofi and Regeneron Approved by FDA for Eosinophilic Esophagitis in Younger Pediatric Patients

Fineline Cube Jan 29, 2024

The US Food and Drug Administration (FDA) has concluded a priority review and granted approval...

Company Deals Drug

Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101

Fineline Cube Jan 29, 2024

Shandong Boan Biotechnology Co., Ltd (HKG: 6955), based in China, has announced a licensing agreement...

Posts pagination

1 … 429 430 431 … 688

Recent updates

  • AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older
  • Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval
  • Eli Lilly’s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use
  • Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax
  • J&J’s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older

Company Drug

Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval

Company Drug

Eli Lilly’s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use

Company Deals

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.